Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. SALAZOPYRINE (sulfasalazine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

SALAZOPYRINE (sulfasalazine)

Medicine - Posted on May 17 2019 - Updated on Jun 12 2019
Active substance (DCI)
  • sulfasalazine
history (3)
  • 2/20/19

    SALAZOPYRINE (sulfasalazine)

    Maintien de l’intérêt clinique important dans la polyarthrite rhumatoïde (PR) Intérêt clinique désormais insuffisant pour ju...
    icône flèche
  • 7/23/14

    SALAZOPYRINE

    Non-biologic DMARDs in rheumatoid arthritis (excluding methotrexate and leflunomide) Azathioprine, sulfasalazine and synthet...
    icône flèche
  • 10/24/07

    SALAZOPYRINE (sulfasalazine)

    Le SMR dans la maladie de Crohn passe de important à modéré. Pas de changement dans les autres indications. ...
    icône flèche
Technical information
ATC code
  • A07EC01
Manufacturer
PFIZER PFE FRANCE
Presentation

SALAZOPYRINE 500 mg, comprimé enrobé gastro-résistant (code CIS : 67124724) 1 flacon de 100 comprimés - Code CIP : 34009 322 688 0 1

All our publications
    Autoimmune diseases Drug therapy Esophageal and gastrointestinal diseases Joint and rheumatic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
6XywqgFBgzhVqGcs